Search

Jagan N Thupari

from Owings Mills, MD
Age ~79
Get Report
Also known as:
Jagan Nath Thupari, Jagan Nath, Jagan N Thurar, Jaygan Thupari, Jagan I
Phone and address:
3701 Thoroughbred Ln, Garrison, MD 21117
(410) 356-3169
Related to:
Neill Thupari, 76Amor N Thupari, 35Molina Thupari, 76Molly Thupari, 62Roop K Thupari
Connected to:
Shelby L Thur, 30William Thur, 51Valerie C Thurab, 69Peter A Thuranszky, 34Becky A Thurau, 69Jeanine R Thurau, 62Jennifer Thurau, 52Amie Thurber, 48Bliss M Thurber, 39Carolyn L Thurber, 59

Jagan Thupari Phones & Addresses

  • 3701 Thoroughbred Ln, Owings Mills, MD 21117 (410) 356-3169
  • Nottingham, MD
  • 3701 Thoroughbred Ln, Owings Mills, MD 21117 (443) 413-4525

Work

Position: Professional/Technical

Education

Degree: Graduate or professional degree

Emails

m***[email protected]

Resumes

Resumes

Jagan Thupari Photo 1

Assistant Professor

View page
Location:
Baltimore, MD
Industry:
Higher Education
Work:
Johns Hopkins University
Assistant Professor
Jagan Thupari Photo 2

Adjunct Assistant Professor

View page
Location:
319 Ringold Valley Cir, Cockeysville, MD 21030
Industry:
International Trade And Development
Work:
Johns Hopkins University Department of Pathology Som Jun 2005 - Jun 2008
Assistant Professor
Johns Hopkins University Jun 2005 - Jun 2008
Adjunct Assistant Professor
Johns Hopkins School of Medicine Jun 2005 - Jun 2008
Adjunct Assistant Professor
Education:
The Johns Hopkins University - Carey Business School 2000 - 2001
Masters P.g. College of Law, Basheerbagh 1976 - 1978
Doctor of Medicine, Doctorates, Microbiology, Immunology
Skills:
Grant Writing Medical Sciences
Teaching Science
Jagan Thupari Photo 3

Assistant Professor At Johns Hopkins University

View page
Position:
Assistant Professor at Johns Hopkins University
Location:
Baltimore, Maryland Area
Industry:
Research
Work:
Johns Hopkins University
Assistant Professor
Jagan Thupari Photo 4

Jagan Thupari

View page

Publications

Us Patents

Stimulation Of Cpt-1 As A Means To Reduce Weight

View page
US Patent:
20050106217, May 19, 2005
Filed:
Aug 13, 2004
Appl. No.:
10/917525
Inventors:
Jagan Thupari - Owings Mills MD, US
Leslie Landree - Baltimore MD, US
Gabriele Ronnett - Lutherville MD, US
Francis Kuhajda - Lutherville MD, US
Assignee:
JOHNS HOPKINS UNIVERSITY LICENSING AND TECHNOLOGY DEVELOPMENT - Baltimore MD
International Classification:
A61K031/198
A61K047/00
US Classification:
424439000, 514565000
Abstract:
This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for development of therapeutics that selectively enhance fatty acid oxidation, increase energy production, and reduce adiposity while preserving lean mass, through the pharmacological stimulation of CPT-1 activity. In a preferred mode, the agent is administered in an amount sufficient to increase fatty acid oxidation. In another preferred mode, the agent is administered in an amount sufficient to antagonize malonyl CoA inhibition of CPT-1. In yet another preferred mode, the agent is administered in an amount sufficient to increase malonyl CoA level.

Stimulation Of Cpt-1 As A Means To Reduce Weight

View page
US Patent:
20050143467, Jun 30, 2005
Filed:
Feb 10, 2003
Appl. No.:
10/503605
Inventors:
Jagan Thupari - Owings Mills MD, US
Gabrielle Ronnett - Lutherville MD, US
Francis Kuhajda - Lutherville MD, US
Assignee:
The Johns Hopkins University School of Medicine Licensing and Technology Development - Baltimore MD
International Classification:
A61K031/198
A61K031/365
US Classification:
514565000, 514471000
Abstract:
This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for development of therapeutics that selectively enhance fatty acid oxidation, increase energy production, and reduce adiposity while preserving lean mass, through the pharmacological stimulation of CPT-1 activity. In a preferred mode, the agent is administered in an amount sufficient to increase fatty acid oxidation. In another preferred mode, the agent is administered in an amount sufficient to antagonize malonyl CoA inhibition of CPT-1. In yet another preferred mode, the agent is administered in an amount sufficient to increase malonyl CoA level.

Novel Compounds, Pharmaceutical Compositions Containing Same, And Methods Of Use For Same

View page
US Patent:
20060241177, Oct 26, 2006
Filed:
Jul 1, 2003
Appl. No.:
10/519804
Inventors:
Susan Medghalchi - Baltimore MD, US
Jagan Thupari - Baltimore MD, US
Craig Townsend - Baltimore MD, US
Jill McFadden - Baltimore MD, US
International Classification:
A61K 31/365
C07D 305/12
US Classification:
514471000, 514473000, 549321000
Abstract:
Pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IX: R═H, or C-Calkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, ═CHR, —C(O)OR, —C(O)R, —CHC(O)OR, CHC(O)NHR, where Ris H or C-Calkyl, cycloalkyl, or alkenyl; R═C-Calkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl; X═—OR, or NHR, Where Ris H, C-Calkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, the Rgroup optionally containing a carbonyl group, a carboxyl group, a carboxyamide group, an alcohol group, or an ether group, the Rgroup further optionally containing one or more halogen atoms; with the proviso that when Ris ═CH, then Xis not OH. Also disclosed are compounds within the scope of the formula IX, as well as uses of the pharmaceutical compositions for weight loss, anti-microbial and anti-cancer applications, inhibition of fatty acid synthase and neuropeptide-Y, and the stimulation of the activity of carnitine palmitoyl transferase-1.

Novel Compounds, Pharmaceutical Compositions Containing Same, And Methods Of Use For Same

View page
US Patent:
20060247302, Nov 2, 2006
Filed:
Jul 9, 2003
Appl. No.:
10/520505
Inventors:
Francis Kuhajda - Baltimore MD, US
Susan Medghalchi - Baltimore MD, US
Jill McFadden - Baltimore MD, US
Jagan Thupari - Baltimore MD, US
Assignee:
FASgen, Inc. - Baltimore MD
Johns Hopkins University - Baltimore MD
International Classification:
A61K 31/381
C07D 333/32
US Classification:
514445000, 549062000
Abstract:
A pharmaceutical composition comprising a phamaceurtical diluent and a compound of formula IV wherein R═H, C-Calkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CHOR, —C(O)R, —CO(O)R, —C(O)NRR, —CHC(O)R, or —CHC(O)NHR, where Rand Rare each independently H, C-Calkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R═—OH, —OR, —OCHC(O)R, —OCHC(O)NHR, —OC(O)R, —OC(O)OR, —OC(O)NHNH—R, or —OC(O)NRR, where Rand Rare each independently H, C-Calkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where Rand Rcan each optionally contain halogen atoms; Rand R, the same or different from each other, are C-Calkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and/or fatty acid synthase, and to stimulate CPT-1.

Stimulation Of Cpt-1 As A Means To Reduce Weight

View page
US Patent:
20070087037, Apr 19, 2007
Filed:
Oct 2, 2006
Appl. No.:
11/537968
Inventors:
Jagan THUPARI - Owings Mills MD, US
Leslie Landree - Baltimore MD, US
Gabrielle Ronnett - Lutherville MD, US
Francis Kuhajda - Lutherville MD, US
Assignee:
The Johns Hopkins University School of Medicine Licensing and Technology Development - Baltimore MD
International Classification:
A61K 47/00
A61K 31/205
US Classification:
424439000, 514554000
Abstract:
This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for development of therapeutics that selectively enhance fatty acid oxidation, increase energy production, and reduce adiposity while preserving lean mass, through the pharmacological stimulation of CPT-1 activity. In a preferred mode, the agent is administered in an amount sufficient to increase fatty acid oxidation. In another preferred mode, the agent is administered in an amount sufficient to antagonize malonyl CoA inhibition of CPT-1. In yet another preferred mode, the agent is administered in an amount sufficient to increase malonyl CoA level.

Control Of Feeding Behavior By Changing Neuronal Energy Balance

View page
US Patent:
20080119548, May 22, 2008
Filed:
Mar 18, 2005
Appl. No.:
10/593090
Inventors:
Gabrielle V. Ronnett - Baltimore MD, US
Frankcis P. Kuhajda - Baltimore MD, US
Jagan N. Thupari - Baltimore MD, US
Leslie E. Landree - Baltimore MD, US
Timothy H. Moran - Baltimore MD, US
Eun-Kyoung Kim - Baltimore MS, US
International Classification:
A61K 31/341
A61P 3/04
US Classification:
514473
Abstract:
Obesity is a worldwide health issue, affecting children and adults in developed and developing countries. Obesity is a disorder of both energy metabolism and appetite regulation, and may be understood as a dysfunction of energy balance. Applicants have found a means for regulating food intake by a subject by administering a compound to the subject which affects neuronal energy balance. Applicants have found a means for regulating food intake by a subject administering a compound to the subject which targets the activity of AMPK, in particular inhibiting activation, in particular hypothalamic. Applicants have also found a method of inducing weight loss in a subject by decreasing the subjects appetite by administering a compound to the subject which increases the subject's neuronal energy balance.

Stimulation Of Cpt-1 As A Means To Reduce Weight

View page
US Patent:
20090124684, May 14, 2009
Filed:
Nov 6, 2008
Appl. No.:
12/266425
Inventors:
Jagan N. Thupari - Owings Mills MD, US
Leslie E. Landree - Baltimore MD, US
Gabrielle Ronnett - Lutherville MD, US
Francis P. Kuhajda - Lutherville MD, US
Assignee:
The Johns Hopkins University School of Medicine Licensing and Technology Development - Baltimore MD
International Classification:
A61K 31/381
A61K 31/365
C12Q 1/48
US Classification:
514445, 514473, 435 15
Abstract:
This invention provides methods and compositions for inducing weight loss and maintaining optimum weight comprising administering an agent that stimulates carnitine palmitoyl transferase-1 (CPT-1) activity to the patient in need, including human patients. These methods do not require inhibition of fatty acid synthesis. In particular, this invention provides methods for development of therapeutics that selectively enhance fatty acid oxidation, increase energy production, and reduce adiposity while preserving lean mass, through the pharmacological stimulation of CPT-1 activity. In a preferred mode, the agent is administered in an amount sufficient to increase fatty acid oxidation. In another preferred mode, the agent is administered in an amount sufficient to antagonize malonyl CoA inhibition of CPT-1. In yet another preferred mode, the agent is administered in an amount sufficient to increase malonyl CoA level.

Novel Compounds, Pharmaceutical Compositions Containing Same, And Methods Of Use For Same

View page
US Patent:
20100120901, May 13, 2010
Filed:
Jan 13, 2010
Appl. No.:
12/686691
Inventors:
Francis P. Kuhajda - Baltimore MD, US
Susan M. Medghalchi - Baltimore MD, US
Jill M. McFadden - Baltimore MD, US
Jagan Thupari - Baltimore MD, US
Craig A. Townsend - Baltimore MD, US
Assignee:
FASGEN,INC - Baltimore MD
THE JOHNS HOPKINS UNIVERSITY - Baltimore MD
International Classification:
A61K 31/381
C07D 333/32
A61P 3/00
A61P 31/00
US Classification:
514445, 549 62, 549 65, 549 66
Abstract:
A pharmaceutical composition comprising a pharmaceutical diluent and a compound of formula IV wherein R=H, C-Calkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, —CHOR, —C(O)R, —CO(O)R, —C(O)NRR, —CHC(O)R, or —CHC(O)NHR, where Rand Rare each independently H, C-Calkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, optionally containing one or more halogen atoms. R=—OH, —OR, —OCHC(O)R, —OCHC(O)NHR, —OC(O)R, —OC(O)OR, —OC(O)NHNH—R, or —OC(O)NRR, where Rand Rare each independently H, C-Calkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl, and where Rand Rcan each optionally contain halogen atoms; Rand R, the same or different from each other, are C-Calkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. Methods of using such formulations for the treatment of cancer, to effect weight loss, to treat microbially-based infections, to inhibit neuropeptide-Y and/or fatty acid synthase, and to stimulate CPT-1.
Control profile
Jagan N Thupari from Owings Mills, MD, age ~79 Get Report